Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients

Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients

PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy, announced today optimistic results from its ongoing clinical trial evaluating LAM561...

Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem

Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem

Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026 SYDNEY, Feb. 5, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary...

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial Officer, Andrew Udell Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media....

menu
menu